BRAF and melanoma: Although complete inhibition of the MAPK pathway was already achieved at nanomolar concentrations of trametinib, there was almost no induction of apoptosis in BRAF-WT melanoma cells within three days of treatment with MEKi, as indicated by the absence of sub-G1 cells in the cell cycle analysis (Fig. 1C).